Health Industry Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.

Press releases published on October 5, 2026

Oct. 5, 2026

キュリア、無菌API製造に2800万ドル (約44億円) を投資

Indeterminate GlobeNewswire

Oct. 5, 2026

Curia, 무균 API 생산에 2,800만 달러 투자

Indeterminate GlobeNewswire

Oct. 5, 2026

Curia Melabur AS$28 Juta dalam Pengeluaran API Steril

Indeterminate GlobeNewswire

Oct. 5, 2026

Curia Investe US$ 28 Milhões na Fabricação de IFAs Estéreis

Indeterminate GlobeNewswire

Oct. 5, 2026

Curia ลงทุน 28 ล้านดอลลาร์สหรัฐฯ ในการผลิตสารออกฤทธิ์ทางเภสัชกรรม (Active Pharmaceutical Ingredient: API) ปลอดเชื้อ

Indeterminate GlobeNewswire

Oct. 5, 2026

Curia 投资 2,800 万美元扩大无菌原料药产能

Indeterminate GlobeNewswire

Oct. 5, 2026

Curia 投資 2,800 萬美元於無菌有效藥劑成分製造

Indeterminate GlobeNewswire

Oct. 5, 2026

Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress

Indeterminate GlobeNewswire

Oct. 5, 2026

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

Indeterminate GlobeNewswire

Oct. 5, 2026

RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab

Indeterminate GlobeNewswire

Oct. 5, 2026

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

Indeterminate GlobeNewswire

Oct. 5, 2026

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Oct. 5, 2026

Aprea Therapeutics to Present at October Conferences

Indeterminate GlobeNewswire

Oct. 5, 2026

Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026

Indeterminate GlobeNewswire

Oct. 5, 2026

DLH Wins $2 Million NIH Data Governance Pilot Task Order

Indeterminate GlobeNewswire

Oct. 5, 2026

Coverys Reveals 68% of Inpatient Diagnostic Errors Occur on General Medical-Surgical Units

Indeterminate GlobeNewswire

Oct. 5, 2026

Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101

Indeterminate GlobeNewswire

Oct. 5, 2026

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing

Indeterminate GlobeNewswire

Oct. 5, 2026

Ensimmäinen potilas on saanut hoitoa Orion Pharman Faasi 1/2 -tutkimuksessa ODM-216-molekyylillä, joka on yhtiön ensimmäinen kliiniseen kehitysvaiheeseen edennyt biologinen syöpälääkeaihio

Indeterminate GlobeNewswire

Oct. 5, 2026

PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026

Indeterminate GlobeNewswire